Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
Arthritis Research & Therapy|January 5, 2021
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive reviewPaul Emery, Patrick Durez, Axel J Hueber, et al.
Arthritis Care & Research|September 25, 2019
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor PrognosisHarris A Ahmad, Joshua F Baker, Mikkel Østergaard, et al.
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
Clinical Rheumatology|April 4, 2018
Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trialPatrick Durez, Karel Pavelka, Maria Alicia Lazaro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Global molecular effects of tocilizumab therapy in rheumatoid arthritis synoviumJulie Ducreux, Patrick Durez, Christine Galant, et al.
Rheumatology and Therapy|May 14, 2023
Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels CohortEmilie Sapart, Tatiana Sokolova, Stéphanie de Montjoye, et al.
Rheumatology (Oxford, England)|September 19, 2023
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritisClément Triaille, Pierre Quartier, Lien De Somer, et al.
Clinical Rheumatology|May 13, 2018
Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trialPatrick Durez, Karel Pavelka, Maria Alicia Lazaro, et al.
Arthritis Research & Therapy|September 30, 2025
Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohortFrancesco Natalucci, Clément Triaille, Emilie Sapart, et al.
The Journal of Rheumatology|October 3, 2006
Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritisMichael H Weisman, Patrick Durez, David Hallegua, et al.
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
Arthritis Research & Therapy|January 5, 2021
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive reviewPaul Emery, Patrick Durez, Axel J Hueber, et al.
Arthritis Care & Research|September 25, 2019
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor PrognosisHarris A Ahmad, Joshua F Baker, Mikkel Østergaard, et al.
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
Clinical Rheumatology|April 4, 2018
Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trialPatrick Durez, Karel Pavelka, Maria Alicia Lazaro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Global molecular effects of tocilizumab therapy in rheumatoid arthritis synoviumJulie Ducreux, Patrick Durez, Christine Galant, et al.
Rheumatology and Therapy|May 14, 2023
Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels CohortEmilie Sapart, Tatiana Sokolova, Stéphanie de Montjoye, et al.
Rheumatology (Oxford, England)|September 19, 2023
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritisClément Triaille, Pierre Quartier, Lien De Somer, et al.
Clinical Rheumatology|May 13, 2018
Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trialPatrick Durez, Karel Pavelka, Maria Alicia Lazaro, et al.
Arthritis Research & Therapy|September 30, 2025
Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohortFrancesco Natalucci, Clément Triaille, Emilie Sapart, et al.
The Journal of Rheumatology|October 3, 2006
Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritisMichael H Weisman, Patrick Durez, David Hallegua, et al.
Pageof 12